SAN
DIEGO, May 3, 2023 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that
Dr. Helen Torley, president and
chief executive officer, is scheduled to present and host investor
meetings at the following investor conferences.
Details of the presentations are as follow:
Event:
|
|
|
|
BofA Securities 2023
Health Care Conference
|
Format:
|
|
|
|
Corporate Presentation
and 1x1 Meetings
|
Presentation
Date:
|
|
|
|
Wednesday, May 10,
2023
|
Presentation
Time:
|
|
|
|
4:20 p.m. PT / 7:20
p.m. ET
|
Location:
|
|
|
|
Las Vegas,
NV
|
|
|
|
|
|
Event:
|
|
|
|
JMP Securities Life
Sciences Conference
|
Format:
|
|
|
|
Fireside Chat and 1x1
Meetings
|
Presentation
Date:
|
|
|
|
Monday, May 15,
2023
|
Presentation
Time:
|
|
|
|
10:30 a.m. PT / 1:30
p.m. ET
|
Location:
|
|
|
|
New York, NY
|
Event:
|
|
|
|
Benchmark Healthcare
House Call Investor Conference
|
Format:
|
|
|
|
1x1 Meetings
|
Date:
|
|
|
|
Tuesday, May 23,
2023
|
Location:
|
|
|
|
Virtual
|
A live audio webcast of the BofA and JMP Securities
presentations will be available in the Investor Relations
section of the Company's website. Replays of the audio webcast
will be available for 90 days following the conference.
About Halozyme Therapeutics, Inc.
Halozyme is a
biopharmaceutical company bringing disruptive solutions to
significantly improve patient experiences and outcomes for emerging
and established therapies. As the innovators of the
ENHANZE® technology with the proprietary enzyme rHuPH20,
Halozyme's commercially-validated solution is used to facilitate
the delivery of injected drugs and fluids in order to reduce the
treatment burden to patients. Having touched more than 700,000
patient lives in post-marketing use in five commercialized products
across more than 100 global markets, Halozyme has licensed its
ENHANZE® technology to leading pharmaceutical and biotechnology
companies including Roche, Takeda, Pfizer, AbbVie, Eli Lilly,
Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV
Healthcare and Chugai Pharmaceutical.
Halozyme also develops, manufactures and commercializes, for
itself or with partners, drug-device combination products using its
advanced auto-injector technology that are designed to provide
commercial or functional advantages such as improved convenience
and tolerability, and enhanced patient comfort and adherence. The
Company has a commercial portfolio of proprietary products
including XYOSTED®, TLANDO® and
NOCDURNA® and partnered commercial products and
ongoing product development programs with several pharmaceutical
companies including Teva Pharmaceutical, Pfizer and Idorsia
Pharmaceuticals.
Halozyme is headquartered in San
Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations
facility.
For more information visit www.halozyme.com and connect with us
on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@antarespharma.com
Dawn Schottlandt / Claudia Styslinger
Argot Partners
212-600-1902
Halozyme@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halozyme-to-present-at-upcoming-investor-conferences-301814337.html
SOURCE Halozyme Therapeutics, Inc.